RP-5063 Completed Phase 2 Trials for Acute Schizophrenia / Schizoaffective Disorders Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01490086RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder